Insulin Icodec

Summary

Insulin Icodec (CHEMBL4594581) is an approved protein (ATC A10AE07); indicated across 3 conditions including type 2 diabetes mellitus and diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: A10AE07
• Indications: 3 conditions
• Clinical trials: 32

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594581
Name	Insulin Icodec
Type	Protein
Max phase	4
ATC	A10AE07

Also known as: Awiqli, Insulin 287, Insulin icodec, Long-acting-insulin-287, NN1436, NNC01480287, INSULIN ICODEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	4	MONDO:0005148	MONDO:0005148
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 1 diabetes mellitus	4	MONDO:0005147	MONDO:0005147

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
PHASE1	15
PHASE3	11
PHASE2	3
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07112339	PHASE4	RECRUITING	A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07076199	PHASE3	RECRUITING	A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT04460885	PHASE3	COMPLETED	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
NCT04760626	PHASE3	COMPLETED	A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
NCT04770532	PHASE3	COMPLETED	A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
NCT04795531	PHASE3	COMPLETED	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
NCT04848480	PHASE3	COMPLETED	A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
NCT04880850	PHASE3	COMPLETED	A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
NCT05352815	PHASE3	COMPLETED	A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05813912	PHASE3	COMPLETED	A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
NCT05823948	PHASE3	COMPLETED	A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
NCT06340854	PHASE3	COMPLETED	A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
NCT03751657	PHASE2	COMPLETED	A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
NCT03922750	PHASE2	COMPLETED	A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
NCT03951805	PHASE2	COMPLETED	A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
NCT01809184	PHASE1	COMPLETED	A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
NCT02148861	PHASE1	COMPLETED	A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
NCT02964104	PHASE1	COMPLETED	A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
NCT03723772	PHASE1	COMPLETED	A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
NCT03723785	PHASE1	COMPLETED	A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems
NCT03766854	PHASE1	COMPLETED	A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week
NCT03789578	PHASE1	COMPLETED	A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
NCT03945656	PHASE1	COMPLETED	A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
NCT04582435	PHASE1	COMPLETED	A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes
NCT04582448	PHASE1	COMPLETED	A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes
NCT04597697	PHASE1	COMPLETED	A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease
NCT04857398	PHASE1	COMPLETED	A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
NCT05435677	PHASE1	COMPLETED	A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
NCT05790681	PHASE1	COMPLETED	A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
NCT06288412	PHASE1	COMPLETED	A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
NCT06807190	Not specified	RECRUITING	General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
NCT07160816	Not specified	RECRUITING	A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).